Faculty profile

David Cherney

ResearcherMedicine/NephrologyUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

David Cherney

Researcher

Medicine/Nephrology

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
29 publications in the last five years, latest in 2026.
Senior (last) author on 2 recent papers, a sign of leading a research group.
Principal investigator on 7 research grants (7 CIHR), most recently in 2026.
Supervised 4 trainees who won CIHR awards, most recently in 2025.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

426

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Albuminuria Diabetes Mellitus Cardiovascular Disease Biological Sex Blood Pressure Diabetes Gfr Slope Glycemic Control

Latest papers

Post-Hoc Analysis on the Effects of Vicadrostat/Empagliflozin by CKD Severity/Hypertension Status.
Kidney international reports · 2026
The Muscle Cramp Impact Index: A Patient-Centered Scale for the Assessment of Muscle Cramps.
Neurology · 2026
Next-generation therapeutics for diabetic kidney disease.
Nature reviews. Nephrology · 2026 · senior author

All 53 publications

Latest funding

Adding AcetazolamIde on top of SGLT2 inhibition in Type 2 Diabetes and Albuminuria ('DIPPER') Study
CIHR · 2026 · Nominated PI
$761,176
INTEGRATE-CKD - INcreasing The uptakE of Guideline diRected medicAl TherapiEs in CKD
CIHR · 2025 · Supervisor
$140,000
Sodium glucose co-transporter inhibition in heart failure with preserved ejection fraction: the autonomic-cardio-renal axis
CIHR · 2024 · Supervisor
$210,000

All 15 grants and awards

53 publications.

Post-Hoc Analysis on the Effects of Vicadrostat/Empagliflozin by CKD Severity/Hypertension Status.

Correa-Rotter R, Rossing P, Canziani ME, Caramori ML, Cherney D, Cronin L, Hugo C, Ji B, Meyerhoff J, Nangaku M, Silva A, Urbach D, Shah SV, de Zeeuw D, Tuttle KR

Kidney international reports2026

DOI: 10.1016/j.ekir.2026.106545 PMID: 42292647

The Muscle Cramp Impact Index: A Patient-Centered Scale for the Assessment of Muscle Cramps.

Katzberg HD, Bril V, Zinman L, Abrahao A, Cherney D, Shah H, Mendoza MG, Alfaidi N, Alnajjar S, Barnett-Tapia C

Neurology2026

DOI: 10.1212/wnl.0000000000214835 PMID: 41955555

Next-generation therapeutics for diabetic kidney disease.

Yi TW, Sridhar VS, Scott J, Nardone M, Cherney D

Nature reviews. Nephrology2026Senior author

DOI: 10.1038/s41581-025-01042-0 PMID: 41526484

Mechanisms of SGLT inhibitor action and physiological mediators: systematic review and protocol for the MOSAIC collaborative meta-analysis.

Kugathasan L, Nardone M, Muskiet MHA, Diaz Martinez JP, Lovblom LE, Orchanian-Cheff A, Nielsen S, Rotbain V, Kazup A, Cersosimo E, Gullaksen S, Vernstrom L, van Baar MJB, van Bommel E, Kannenkeril D, Scholtes R, Hesp A, Mosterd C, Touw DJ, Lambers Heerspink H, Krebbe M, Joles J, Kvitne K, Laugesen E, Mose F, Mårup FH, Nieuwdorp M, Geist B, Maruyama S, Kato S, Kalambokis G, Tsiakas I, Jensen J, Schou M, Omar M, Kistorp CM, Perna A, Ruggenenti P, Persson F, Schmieder R, Singh S, van Raalte DH, Cherney D, Srinivasan Sridhar V

BMJ open2026

DOI: 10.1136/bmjopen-2025-108946 PMID: 41748173

Effects of Acoramidis on Kidney Function in Transthyretin Amyloid Cardiomyopathy.

Testani JM, Judge DP, Borlaug BA, Cherney D, Cox ZL, Gillmore JD, Lewis JB, Adler SH, Cao X, Castaño A, Fox JC, Katz L, Mathur V, Xiong K, Butler J, Masri A

Circulation. Heart failure2026

DOI: 10.1161/circheartfailure.126.014656 PMID: 42389794

Chronic kidney disease screening to reduce cardiovascular risk: a call to action.

Michos ED, Cherney D, Kushner P

American journal of preventive cardiology2026

DOI: 10.1016/j.ajpc.2025.101380 PMID: 41613347

The Role of Inflammation and High-Sensitivity C-Reactive Protein in Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease: The FLAME-ASCVD Survey among Nephrologists.

Perkovic V, Cherney D, Erazo-Tapia E, Gerward S, Waechter S, Sahay M, Marx N

Cardiorenal medicine2026

DOI: 10.1159/000550094 PMID: 41406048

Authors' Reply: Tirzepatide and Kidney Protection in Obesity: Unanswered Questions.

Heerspink HJL, Bjornstad P, Cherney D, van Raalte DH

Journal of the American Society of Nephrology : JASN2025

DOI: 10.1681/asn.0000000838 PMID: 40960873

Cost-effectiveness of finerenone therapy for patients with chronic kidney disease and type 2 diabetes in England & Wales: results of the FINE-CKD model.

Cherney D, Drzewiecka A, Folkerts K, Levy P, Millier A, Morris S, Pochopień M, Roy-Chaudhury P, Sullivan SD, Mernagh P

Journal of medical economics2025First author

DOI: 10.1080/13696998.2025.2451526 PMID: 39783822

Kidney Parameters with Tirzepatide in Obesity with or without Type 2 Diabetes.

Heerspink HJL, Friedman AN, Bjornstad P, van Raalte DH, Cherney D, Cao D, Garcia-Pérez LE, Stefanski A, Turfanda I, Bunck MC, Benabbad I, Griffin R, Piras de Oliveira C

Journal of the American Society of Nephrology : JASN2025

DOI: 10.1681/asn.0000000764 PMID: 40512543

Adding AcetazolamIde on top of SGLT2 inhibition in Type 2 Diabetes and Albuminuria ('DIPPER') Study

Nominated PICIHR2026Project Grant

Principal investigators: Cherney, David Z; Connelly, Kim A; Levin, Adeera; Odutayo, Ayodele; Perkins, Bruce A; Srinivasan Sridhar, Vikas

Keywords: Acetazolamide; Albuminuria; Chronic Kidney Disease; Glomerular Filtration Rate; Sglt2 Inhibitor; Type 2 Diabetes

$761,176

INTEGRATE-CKD - INcreasing The uptakE of Guideline diRected medicAl TherapiEs in CKD

SupervisorCIHR2025Canada Postdoctoral Research Award (CPRA) program

Principal investigators: Yi, Tae Won

Keywords: Chronic Kidney Disease; Diabetes; Guideline Based Medical Therapies; Heart Failure; Knowlege Translation

$140,000

Sodium glucose co-transporter inhibition in heart failure with preserved ejection fraction: the autonomic-cardio-renal axis

SupervisorCIHR2024CIHR Fellowship

Principal investigators: Nardone, Massimo

Keywords: Heart Failure; Kidney Function; Sglt2 Inhibitors; Sympathetic Nervous System

$210,000

Expanding the use of SGLT-2 inhibitor to improve cardiorenal disease

SupervisorCIHR2023CIHR REDI Early Career Transition Award - Kidney Health

Principal investigators: Odutayo, Ayodele

Keywords: Cardiovascular Disease; Chronic Kidney Disease; Sodium Glucose Co-Transporter 2 Inhibitors

$98,750

Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis (GUARD-1)

Principal investigatorCIHR2023Project Grant

Principal investigators: Wald, Ron; Cherney, David Z; Clemens, Kristin K; Yau, Kevin

Keywords: Diabetes Mellitus; Dialysis; End-Stage Kidney Disease; Glp-1 Receptor Agonists; Pilot Rct

$566,099

SodiUm Glucose co-trAnspoRt-2 inhibitioN diabeteS And and kidney function Loss in Type 1 diabetes: The "SUGARNSALT" Team Grant Program

Nominated PICIHR2021Team Grant: DM/TS - CIHR-KFOC - Diabetic Kidney Disease

Principal investigators: Cherney, David Z; Campbell, David J; Layton, Anita; Perkins, Bruce A

Keywords: Albuminuria; Biological Sex; Blood Pressure; Cardiovascular Disease; Diabetes; Gfr Slope; Glycemic Control; Kidney Health And Disease; Patient Oriented Research; Sglt2 Inhibition

$992,774

Disturbances of neurogenic cardiovascular control in heart failure with preserved ejection fraction

Co-investigatorCIHR2021Project Grant

Principal investigators: Floras, John S

Keywords: Autonomic Nervous System; Baroreceptor Reflexes; Cardiovascular Rehabilitation; Endothelial Function; Exercise; Human Heart Failure; Microneurography; Ventricular Function; Women

$485,774

Efficacy, mechanisms, and safety of SGLT2 inhibitors in kidney transplant recipients

SupervisorCIHR2020Doctoral Research Award: Canada Graduate Scholarships

Principal investigators: Srinivasan Sridhar, Vikas

Keywords: Blood Pressure; Kidney Transplant Recipients; Natriuresis; Post Transplant Diabetes Mellitus; Renal Hemodynamics; Sodium-Glucose Cotransporter 2 Inhibitors; Type 2 Diabetes

$105,000

SodiUm Glucose co-trAnspoRt-2 inhibitioN diabeteS And and kidney function Loss in Type 1 diabetes: The "SUGARNSALT" Team Grant Program

Nominated PICIHR2020Team Grant: DM/TS - CIHR-KFOC - Diabetic Kidney Disease - LOI

Principal investigators: Cherney, David Z; Campbell, David J; Layton, Anita; Perkins, Bruce A

Keywords: Albuminuria; Biological Sex; Blood Pressure; Cardiovascular Disease; Diabetes; Gfr Slope; Glycemic Control; Kidney Health And Disease; Patient Oriented Research; Sglt2 Inhibition

$10,000

Adolescent Type 1 diabetes Treatment with EMPaglifozin for hyperglycemia & hyperfilTration Trial, "ATTEMPT" Trial

Principal investigatorCIHR2017Operating Grant: SPOR & JDRF - ICT Multi-Year Grant

Principal investigators: Mahmud, Farid; Huang, Lennox; Manns, Braden J; McArthur, Lynne; Anthony, Samantha J; Cherney, David Z; Clarson, Cheril L; Daneman, Denis; Harrington, Jennifer; Mertens, Luc; Sochett, Etienne B

Keywords: Adolescence; Cardiovascular Disease; Diabetes Mellitus; Diabetic Nephropathy; Hyperfiltration; Metabolic Control; Patient-Oriented Research; Randomized Controlled Trial

$843,990

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

David Cherney

Research

Latest papers

Latest funding

Post-Hoc Analysis on the Effects of Vicadrostat/Empagliflozin by CKD Severity/Hypertension Status.

The Muscle Cramp Impact Index: A Patient-Centered Scale for the Assessment of Muscle Cramps.

Next-generation therapeutics for diabetic kidney disease.

Mechanisms of SGLT inhibitor action and physiological mediators: systematic review and protocol for the MOSAIC collaborative meta-analysis.

Effects of Acoramidis on Kidney Function in Transthyretin Amyloid Cardiomyopathy.

Chronic kidney disease screening to reduce cardiovascular risk: a call to action.

The Role of Inflammation and High-Sensitivity C-Reactive Protein in Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease: The FLAME-ASCVD Survey among Nephrologists.

Authors' Reply: Tirzepatide and Kidney Protection in Obesity: Unanswered Questions.

Cost-effectiveness of finerenone therapy for patients with chronic kidney disease and type 2 diabetes in England & Wales: results of the FINE-CKD model.

Kidney Parameters with Tirzepatide in Obesity with or without Type 2 Diabetes.

Frequent collaborators

Adeera Levin

Ayodele Odutayo

Subodh Verma

Rahim Moineddin

Bruce Perkins

Etienne Sochett

Satya Dash

Kim Connelly

Mamatha Bhat

Nathan Perlis

Cynthia Tsien

Nadia Giannetti

Louise Moist

Vikas Srinivasan Sridhar

David Cherney

Howard Abrams

Nazia Selzner

Lee Green

Allison Dart

Matthew Lanktree

Robert McKelvie

Karen Harkness

Adam Grzeslo

Shivinder Jolly

Sanjay Pandeya

John Kingdom

Minna Woo

Sheila Dunn

James Scholey

Adeera Levin

Heather Reich

Douglas Lee

Filio Billia